Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFECT OF MORNING AND EVENING RAMIPRIL TAKING ON AMBULATORY BLOOD PRESSURE PROFILE IN PATIENTS WITH ARTERIAL HYPERTENSION

https://doi.org/10.20996/1819-6446-2009-5-1-28-32

Full Text:

Abstract

Aim. To compare antihypertensive effect of ramipril monotherapy at morning and evening taking.

Material and methods. 22 patients (10 men, 12 women; aged 62,1±1,9 y.o.) with arterial hypertension of 1-2 stage were involved into the open randomized crossover study. Patients were randomized into 2 groups depending on ramipril taking time (morning or evening). Ambulatory blood pressure (BP) monitoring (ABPM) was performed. Patients of both groups were comparable in basic clinical characteristics and initial ABPM indices. Analysis of peak and phase characteristics of 24 hour BP profile was used as well as standard evaluation. Treatment duration was 3 weeks. Ramipril dose titration was made in 1,5 weeks. The average daily dose of ramipril was 6,1 mg in the morning taking, and 5,0 mg in the evening taking.

Results. 20 patients finished study completely. 24 hour initial level of systolic (SBP) and diastolic BP (DBP) was 141,5±1,6/85,3±1,1 mm Hg. After ramipril monotherapy with evening taking BP reduced to 132,6±1,6/79,8±1,1 mm Hg (p<0,001) and with morning taking – to 131,8±1,6/79,2±1,1 mm Hg (p<0,001). Evening ramipril taking led to significant improvement of 24 hour BP profile. Night SBP/DBP reduction became deeper from 7,7±1,2/11,5±1,3% to 12,5±1,2/19,1±1,3 % (p<0,01). Morning taking did not have significant influence on these indices. Ramipril did not result in clinically significant hypotension including night one.

Conclusion. Evening ramipril taking is effective and safe. It can be recommended to patients with insufficient night BP dipping (non dippers). 

About the Authors

V. M. Gorbunov
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990


E. J. Fedorova
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990


A. D. Deev
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990


E. V. Platonova
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990


O. J. Isaikina
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990


References

1. Kaplan N.M. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18(4):658-70.

2. Agabiti-Rosei E., Ambrosioni E., Dal Palù C. et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995;13(11):1325-34.

3. Wright J.T. Jr, Bakris G., Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288(19): 2421-2431.

4. Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352(9136):1252-12.

5. Yusuf S., Sleight P., Pogue J. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53.

6. Svensson P., de Faire U., Sleight P. et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001;38(6):E28-32.

7. Zuther P., Witte K., Lemmer B. ABPM-FIT and CV-SORT: an easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring. Blood Press Monit 1996;1(4):347-54.

8. SAS User`s Guide: Statistics, Version 5 Edition. Cary, NC: SAS Institute Inc; 1985.

9. Колос И.П., Мартынюк Т.В., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензин-превращающего фермента рамиприлом и его комбинации с гидрохлортиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследование ХА- РИЗМА. Кардиоваскулярная терапия и профилактика 2008;(2):65-71.

10. Ольбинская А.И., Мартынов А..И., Хапаев Б.А. Мониторирование артериального давления в кардиологии. М.: Русский врач; 1998.

11. Shimada K., Kario K. Altered circadian rhythm of blood pressure and cerebrovascular damage. Blood Press Monit 1997;2(6):333-38.

12. Pickering T.G., Kario K. Nocturnal non-dipping: what does it augur? Curr Opin Nephrol Hypertens 2001;10(5):611-6.

13. Imai Y. Prognostic significance of ambulatory blood pressure. Blood Press Monit 1999;4(5):249-56.

14. Palatini P., Parati G. Modulation of 24-h blood pressure profiles: a new target for treatment? J Hypertens 2005;23(10):1799-801.

15. Hermida R.C., Ayala D.E., Calvo C. et al. Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev 2007;59(9-10):923-39.

16. Staessen J.A., Thijs L., Fagard R. et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999;282(6):539-46.

17. Owens P., O'Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart 1999;82(4):477-81.

18. Watanabe N., Imai Y., Nagai K. et al. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke 1996;27(8):1319-27.


For citation:


Gorbunov V.M., Fedorova E.J., Deev A.D., Platonova E.V., Isaikina O.J. EFFECT OF MORNING AND EVENING RAMIPRIL TAKING ON AMBULATORY BLOOD PRESSURE PROFILE IN PATIENTS WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2009;5(1):28-32. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-1-28-32

Views: 8097


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)